PLx Pharma Winddown Corp.: 10-Q filed 2017-04-17
What PLx Pharma Winddown Corp. reported in its quarterly report filed 2017-04-17 (fiscal Q1 2017): 14 published measures, 30 facts as tagged in accession 0001144204-17-020705.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-04-17
- Fiscal period
- fiscal Q1 2017
- Accession
- 0001144204-17-020705 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PLx Pharma Winddown Corp. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 14,590,474 | USD | |
| At 2016-12-31 | 17,090,873 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 462,136 | USD | |
| At 2016-12-31 | 2,121,893 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 14,128,338 | USD | |
| At 2016-12-31 | 14,968,980 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 12,414,004 | USD | |
| At 2016-12-31 | 16,675,228 | USD | |
| At 2016-03-31 | 4,169,675 | USD | |
| At 2015-12-31 | 5,234,953 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -1,529,865 | USD | 90 |
| 2016-01-01 to 2016-03-31 | -5,816,632 | USD | 91 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 0 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 0 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | -63,912,449 | USD | |
| At 2016-12-31 | -62,382,584 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 689,223 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 1,353,093 | USD | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | -1,567,017 | USD | 90 |
| 2016-01-01 to 2016-03-31 | -5,830,874 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 12,533,844 | USD | |
| At 2016-12-31 | 17,034,243 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 1,567,017 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 5,830,874 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 11,129,747 | shares | |
| At 2016-12-31 | 11,115,747 | shares |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-03-31 | 2,056,630 | USD | |
| At 2016-12-31 | 56,630 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-03-31 | 1,552,329 | USD | 90 |
| 2016-01-01 to 2016-03-31 | 2,247,207 | USD | 91 |
Inspect the source
- Entity
- PLx Pharma Winddown Corp. / CIK 0001497504
- Captured
- SEC response SHA-256
d5fa1894253c4a7ca3d44f3b07f2263d07de14ac7e8983994cead4448c203364
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001497504.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))